Compare Capital One Financial Corp. (COF) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Gilead Sciences, Inc. — how do they compare? Capital One Financial Corp. trades at $219.37 (market cap $134.45B), while Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| COF | GILD | |
|---|---|---|
Market Cap | $134.45B | $168.35B |
Sector | Financials | Health |
52-Week High | $257.94 | $155.80 |
52-Week Low | $176.10 | $110.56 |
Dividend Yield | 1.46% | 2.42% |
Enterprise Value | — | $191.42B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
